Satellos Bioscience (MSLE) Total Non-Current Liabilities (2025 - 2026)
Satellos Bioscience's (MSLE) quarterly Total Non-Current Liabilities came in at -$14.8 million in Q1 2026, down 29.78% on a QoQ basis from -$11.4 million in Q4 2025.
Satellos Bioscience (MSLE) Total Non-Current Liabilities (2025 - 2026) Analysis & Trends
Satellos Bioscience (MSLE) has 2 years of Total Non-Current Liabilities data on file, last reported at -$14.8 million in Q1 2026.
- On a quarterly basis, Total Non-Current Liabilities changed N/A year-over-year to -$14.8 million in Q1 2026; TTM through Mar 2026 was -$14.8 million, a N/A change from a year earlier, with the FY2025 full-year figure at -$11.4 million, changed N/A from the prior year.
- Total Non-Current Liabilities for Q1 2026 stood at -$14.8 million, down from -$11.4 million in the prior quarter.
- Over the last five years, Total Non-Current Liabilities for MSLE reached as high as -$11.4 million in Q4 2025 and fell as low as -$14.8 million in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,140.12 Bn | 66,139.83 Bn | - | 4.45 Mn |
| 2 | Nanobiotix | 1,908.00 Bn | 1,907.94 Bn | - | 110.28 Mn |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | 19.49 Mn |
| 4 | BeOne Medicines | 471.41 Bn | 466.62 Bn | 1.35 Bn | 1.98 Bn |
| 5 | Vertex Pharmaceuticals | 122.15 Bn | 114.90 Bn | 2.59 Bn | 5.87 Bn |
| 6 | Regeneron Pharmaceuticals | 69.94 Bn | 61.18 Bn | 3.31 Bn | 7.32 Bn |
| 7 | Belite Bio | 62.43 Bn | 62.43 Bn | - | - |
| 8 | Argenx Se | 55.85 Bn | 50.67 Bn | 1.41 Bn | 40.00 Mn |
| 9 | Alnylam Pharmaceuticals | 37.48 Bn | 34.47 Bn | 959.66 Mn | 4.05 Bn |
| 10 | Satellos Bioscience | 177.16 Mn | 177.16 Mn | - | -14.76 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -14.76 Mn |
| Dec 31, 2025 | -11.38 Mn |